All Stories

  1. Questionnaire survey among ophthalmic allergists on dupilumab-associated ocular surface disease in Japan

    Article • Allergology International, April 2025, Elsevier

    MD YOKO KATAOKA

  2. Exploring patient background and biomarkers associated with the development of dupilumab-associated conjunctivitis and blepharitis

    Article • Allergology International, April 2024, Elsevier

    MD YOKO KATAOKA, Dr Daisuke Onozuka

  3. Correlation Analysis of Clinician- and Patient-Reported Outcomes Among Japanese Adults with Atopic Dermatitis

    Article • Dermatology and Therapy, February 2024, Springer Science + Business Media

    MD YOKO KATAOKA

  4. Evaluation of standard treatments for managing adult Japanese patients with inadequately controlled moderate‐to‐severe atopic dermatitis: Two‐year data from the ADDRESS‐J disease registry

    Article • The Journal of Dermatology, June 2022, Wiley

    MD YOKO KATAOKA

  5. Dupilumab treatment in patients with atopic dermatitis: a comparative cohort study between the Netherlands and Japan shows a discrepancy in patient‐reported outcome measures

    Article • British Journal of Dermatology, June 2021, Wiley

    MD YOKO KATAOKA

  6. Efficacy and safety of dupilumab in Japanese adults with moderate‐to‐severe atopic dermatitis: a subanalysis of three clinical trials

    Article • British Journal of Dermatology, November 2019, Wiley

    MD YOKO KATAOKA

  7. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2

    Article • Journal of Dermatological Treatment, June 2019, Taylor & Francis

    Professor Luis Puig, Andreas Wollenberg, MD YOKO KATAOKA

  8. Treatment strategies of atopic dermatitis

    Article • The Journal of Dermatology, March 2014, Wiley

    MD YOKO KATAOKA